Elranatamab Fixed Dosing: A Safe, Effective, and Convenient Dosing Approach.

ABSTRACT:

Background

Bispecific T-cell engagers (TCEs) are a promising modality for cancer treatment, and evaluation of dosing strategies, including utilization of body weight-based versus fixed dosing, is essential to ensure optimal therapeutic outcomes. Elranatamab is a bispecific TCE that targets B-cell maturation antigen (BCMA) on multiple myeloma cells and CD on T cells. Elranatamab is approved for relapsed or refractory multiple myeloma (RRMM).

Objective

Evaluate the impact of body weight on the pharmacokinetics (PK), safety, and efficacy of elranatamab.

Patients and methods

Data from the phase 2 MagnetisMM-3 trial (NCT04649359) were used to evaluate the impact of body weight on the PK, safety, and efficacy of elranatamab. This trial comprised two cohorts: cohort A includ

SUBMITTER: Elmeliegy M 

PROVIDER: S-EPMC12454520 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature